ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

ClinicalTrials.gov ID: NCT01979523

Public ClinicalTrials.gov record NCT01979523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma

Study identification

NCT ID
NCT01979523
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
42 participants

Conditions and interventions

Interventions

  • Laboratory Biomarker Analysis Other
  • Pharmacological Study Other
  • Trametinib Drug
  • Uprosertib Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 20, 2013
Primary completion
Aug 31, 2017
Completion
Jul 1, 2026
Last update posted
Apr 12, 2026

2013 – 2026

United States locations

U.S. sites
5
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01979523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01979523 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →